Neurogene (NASDAQ:NGNE) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Neurogene (NASDAQ:NGNEFree Report) in a report published on Thursday morning, Benzinga reports. They currently have a $51.00 target price on the stock.

Several other brokerages have also commented on NGNE. Baird R W upgraded Neurogene to a strong-buy rating in a research report on Tuesday, June 11th. Robert W. Baird assumed coverage on Neurogene in a research report on Tuesday, June 11th. They set an outperform rating and a $54.00 target price on the stock. SVB Leerink assumed coverage on Neurogene in a research report on Monday, April 29th. They set an outperform rating and a $46.00 target price on the stock. William Blair started coverage on Neurogene in a research report on Thursday, March 21st. They set an outperform rating and a $61.00 target price on the stock. Finally, Leerink Partnrs reaffirmed an outperform rating on shares of Neurogene in a research note on Monday, April 29th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Buy and an average target price of $48.60.

Get Our Latest Stock Report on Neurogene

Neurogene Stock Performance

NASDAQ NGNE opened at $31.01 on Thursday. The company has a 50-day moving average of $34.00. Neurogene has a 12 month low of $12.20 and a 12 month high of $53.00.

Neurogene (NASDAQ:NGNEGet Free Report) last released its quarterly earnings results on Friday, May 10th. The company reported ($1.00) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.03. Equities research analysts expect that Neurogene will post -4.15 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. BML Capital Management LLC purchased a new stake in shares of Neurogene in the fourth quarter worth approximately $478,000. Avidity Partners Management LP purchased a new stake in shares of Neurogene in the fourth quarter worth approximately $9,036,000. Great Point Partners LLC purchased a new stake in shares of Neurogene in the fourth quarter worth approximately $19,268,000. Privium Fund Management UK Ltd purchased a new stake in shares of Neurogene in the first quarter worth approximately $274,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Neurogene in the first quarter worth approximately $120,000. 52.37% of the stock is owned by institutional investors and hedge funds.

About Neurogene

(Get Free Report)

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

See Also

Analyst Recommendations for Neurogene (NASDAQ:NGNE)

Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.